Persisting changes in brain glucose uptake following neurotoxic doses of phencyclidine which mirror the acute effects of the drug

Psychopharmacology

Volumn 126, Issue 3, 1996, Pages 271-274

  Ellison, G D ^a   Keys, A S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dementia; Glucose metabolism; Hippocampus; N Methyl D aspartate; Neurotoxicity; Phencyclidine; Psychosis; Schizophrenia

Indexed keywords

CARBON 14; FLUORODEOXYGLUCOSE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BRAIN REGION; CONTROLLED STUDY; ENTORHINAL CORTEX; FEMALE; GLUCOSE TRANSPORT; HIPPOCAMPUS; LIMBIC SYSTEM; NERVE CELL DEGENERATION; NEUROTOXICITY; NONHUMAN; OLFACTORY NUCLEUS; OSMOTIC MINIPUMP; PRIORITY JOURNAL; PSYCHOSIS; PYRIFORM CORTEX; RAT; SHORT SURVEY; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; BRAIN; DEOXYGLUCOSE; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HALLUCINOGENS; PHENCYCLIDINE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0029899485     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02246457     Document Type: Short Survey

References (27)

1. Allen R, Young S (1978) Phencyclidine induced psychosis. Am J Psychiatry 135:1081-1084
2. Aniline O, Pitts F (1982) Phencyclidine (PCP): a review and perspectives. CRC Crit Rev Toxicol 10:145-177
3. 14C-2-deoxyglucose autoradiography. J Neurosci 8:1951-1961
4. Eison M, Eison A, Ellison G (1981) The regional distribution of d-amphetamine and local glucose utilization in rat brain during continous amphetamine administration. Exp Brain Res 43: 281-288
5. Ellison G (1994) Competitive and non-competitive NMDA antagonists induce similar limbic degeneration. Neuro Report 5: 2688-2692
6. Ellison G (1995) The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias. Brain Res Rev 20:250-267
7. Ellison G, Switzer R III (1993) Dissimilar patterns of degeneration in brain following four different addictive stimulants. Neuro Report 5:17-20
8. Keys A (1995) Enduring structural and dynamic alterations in the central nervous system following continuous cocaine exposure. Ph D thesis, University of California
9. Fix A, Wightman K, O'Callaghan J (1995) Reactive gliosis induced by MK-801 in the rat posterior cingulate/retrosplenial cortex: GFAP evaluation by sandwich ELISA and immunocytochemistry. Neurotoxicology 16:229-238
10. Gao X, Shirakawa F, Tamminga C (1993) Delayed regional metabolic actions of phencyclidine. Eur J Pharmacol 241:7-15
11. James S, Schnoll S (1976) Phencyclidine: tissue distribution in the rat. Clin Toxicol 9:573-582
12. Javitt D, Zukin S (1991) Recent advantages in the phencyclidine model of schizophrenia. Am J Psychiatr 148:1301-1308
13. Krystal J, Karper L, Seibyl J, Freeman G, Delancy D, Bremner J, Heninger G, Bowers M Jr, Charney D (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Arch Gen Psychiatry 51:199-214
14. Kurumaji A, McCulloch J (1989) Effects of MK-801 upon local cerebral glucose utilisation in conscious rats and in rats anaesthetised with halothane. J Cereb Bloot Flow Metab 9:786-794
15. Kurumaji A, McCulloch M (1990) Effects of MK-801 upon local cerebral glucose utilisation in conscious rats following unilateral lesion of caudal entorhinal cortex. Brain Res 531:72-82
16. Meltzer H, Holtzman P, Hassan S, Guschwan A (1972) Effects of phencyclidine and stress on plasma CPK and aldolase activity in many. Psychopharmacology 26:44-53
17. Nabeshima T, Sivam S, Tai C, Ho I (1982) Development of dispositional tolerance to phencylidine by osmotic minipump in the mouse. J Pharm Method 7:239-253
18. Nehls D, Kurumaji A, Park C, McCulloch J (1988) Differential effects of competitive and non-competitive N-methyl-D-aspartate antagonists on glucose use in the limbic system. Neurosci Lett 91:204-210
19. Nehls D, Park C, MacCormack A, McCulloch J (1990) The effects of N-methyl-D-aspartate receptor blockade with MK-801 upon the relationship between cerebral blood flow and glucose utilization. Brain Res 511:271-279
20. Olney J, Labruyere J, Price M (1989) Pathological changes induced in cerebrocortical neurons by phenclidine and related drugs. Science 244:1360-1362
21. Sharp F, Sagar F, Swanson R (1993) Metabolic mapping with cellular resolution: c-fos vs 2-deoxyglucose. Crit Rev Neurobiol 7:205-228
22. Tamminga C, Tanimoto K, Kul S, Chase T, Contreras P, Rice K, Jackson A, O'Donohue T (1987) PCP-indnced alterations in cerebral glucose utilization in rat brain: blockade by metaphil, a PCP-receptor-acylating agent. Synapse 1:497-504
23. Tamminga C, Thaker G, Buchanan R, Kirpatrick B, Alphs L, Chase T, Carpenter W (1992) Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry 49:522-530
24. Valentine J, Arnold L, Owens S (1994) Anti-phencyclidine monoclonal Fab fragments markedly alter phencyclidine pharmacokinetics in rats. J Pharmacol Exp Ther 269:1079-1085
25. Waldorf D (1979) A quantitative analysis of 100 PCP users. In: Feldman H, Agar M, Beschner G (eds) Angel dust, an ethnographic study of PCP users. Lexington Books, Lexington, Mass, pp 53-71
26. Weissman A, Marquis K, Moreton J, London E (1989) Effects of self-administered phencyclidine on regional uptake of 2-deoxy-D-1-14C glucose in brain (1989). Neuropharmacology 28: 575-583
27. Wessinger W, Owens S (1991) Phencyclidine dependence: the relationship of dose and serum concentrations to operant behavioral effects. J Pharmacol Exp Ther 258:207-215